PDB59 DEVELOPMENT OF A SCALE FOR DIABETIC PATIENT PROFILING BASED ON PATIENT ATTITUDE TOWARDS INSULIN
Arnould B 1 , Consoli S 2 , Martinez L 3 , Wong O 4 ,Yomtov B 5 , Simon D 6 , Monnier L 7 , Beillat M 8 , Benmedjahed K 9 , Fleury F 10 , Gueron B 8 1 Mapi Values, Lyon, Rhone, France; 2 Georges Pompidou European Hospital, Paris, France; 3 Private Practice, Bois D'arcy, France; 4 Private practice, Paris, France; 5 Henri Mondor, Creteil, France; 6 Pitié Salpétrière, Paris, France; 7 CH Lapeyronie, Montpellier, France; 8 Pfizer, Paris, France; 9 Mapi Values, Lyon, France; 10 Sanofi Aventis, Gentilly, France OBJECTIVE: To develop self-report questionnaires for physician use in the evaluation of diabetic patient reluctance to start or step up insulin regimens. METHODS: An Advisory Committee (AC) was set up. It consisted of 3 diabetes specialists/endocrinologists, 1 behavioural psychiatrist and 2 general practitioners. Three patient focus groups were formed from a pool of 23 type-1 and 2 diabetic patients. Interviewees were asked to list fears, constraints and benefits associated with insulinization, injection and insulin regimen step-up. After analysis of the focus groups, a list of detailed concepts and two test questionnaires were developed and independently validated by the AC with content validity being assessed on 16 type-1 and 2 diabetic patients. Patients completed the questionnaires before being systematically asked to comment on the questionnaire as a whole and more specifically on each element of the questionnaire. Questionnaires were then redrafted and tested on 16 other patients. After analysis of patient tests, a revised questionnaire was produced and validated by the AC. RESULTS: Eleven elements (Insulinization: symbolic, fears, constraints, benefits, product physical characteristics. Injection: symbolic, fears, constraints, positive points. Insulin regimen intensification: symbolic, fears) and 31 detailed concepts were identified using the patient focus groups. Each test questionnaire contained 22 items (20 relating to insulin regimen start or insulin regimen step-up plus 2 relating to inhaled insulin). After initial cognitive debriefing, one item was added, taking each questionnaire to 23 items and response choices were significantly modified in both questionnaires by the AC. After second cognitive debriefing 2 items were excluded from both questionnaires by the AC. The pilot questionnaires therefore included 21 items. CONCLUSION: These pilot questionnaires may help physicians to assess the hurdles faced by diabetic patients in starting or stepping up insulin regimens. The questionnaires are now undergoing item reduction, scoring and validation in two case-report studies.
PDB60 DEVELOPMENT AND EVALUATION OF THE ASK ADHERENCE BARRIER SURVEY IN PATIENTS WITH CHRONIC CONDITIONS
Yu-Isenberg KS 1 , Espindle DM 2 , Skinner EP 1 , Weaver MB 1 , Olson PS 1 , Hahn SR 3 1 GlaxoSmithKline, RTP, NC, USA; 2 Mapi Values USA, Boston, MA, USA; 3 Albert Einstein College of Medicine, Bronx, NY, USA OBJECTIVE: To develop and evaluate a self-report clinical and research adherence barrier survey designed to screen for specific barriers to adherence across a spectrum of chronic conditions. METHODS: Item generation and domain structures were based on literature and expert opinion. Interviews with 33 patients with asthma, diabetes, and heart failure were used to develop 47 Likert-type items. These were tested on the Web with 605 patients with asthma, diabetes, and depression. Factor analysis was performed to identify conceptually similar item groupings; and item validity in relation to a self-reported measure of adherence, the distribution of item responses, and factor structure were studied to select final survey items. RESULTS: Twenty items were retained based on correlation with validity criteria and clinical relevance in the following domains: Lifestyle, Attitudes and Beliefs, Help from Others, Talking with Health care Team, and Difficulty Taking Medicines. A post hoc cut point dichotomizing responses into "present" and "absent" was selected for each item. The Barrier Total Index (BTI), the number of "barrierpresent" items, had an observed range from 0 to 18, a mean of 4.2 (±3.4), and good reliability (Cronbach's alpha = 0.77). The validity of the BTI with a self-report of a missed dose of medicine in the past week was excellent. Patients who "missed" had a mean of 6 barriers vs. 2.6 for those who did not (p < 0.0001). CONCLUSION: The ASK Adherence Barrier Survey appears to be a useful tool to identify barriers to adherence in chronic diseases. The survey can facilitate discussion of adherence and identify opportunities to implement barrier-specific interventions.
PDB61 PERCEIVED HEALTH CARE INFORMATION ON DIABETES: MEASUREMENT OF PATIENT SATISFACTION
Carmosino G 1 , Zerbini O 1 , Comarella L 2 , Morelli P 2 , Balestri M 3 , Brioschi A 3 1 CROM Srl Contract Research Organisation Medical and Pharmaceutical Projects, Verona, Italy; 2 CROS NT Srl, Verona, Italy; 3 Roche Diagnostics, Monza, Italy Patient knowledge on own disease is recognised as key factor to reach therapeutical goals. OBIECTIVE: To develop a questionnaire exploring patient preference on SBGM systems; to measure patient satisfaction on medical information delivered by the hospital health care personnel. METHODS: 454 NIDDM patients,
